November 16, 2016 05:22 PM EST
R&D

Am­gen, No­var­tis are rac­ing to reg­u­la­tors with pos­i­tive PhI­II mi­graine da­ta, but ri­vals are in hot pur­suit

John Carroll

Editor & Founder

It ap­pears that Am­gen and its part­ners at No­var­tis are on a straight path to a new drug ap­proval for their new mi­graine drug erenum­ab …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times